AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

TERN PLC

Regulatory Filings Mar 26, 2019

7958_rns_2019-03-26_c71ca92c-e2a0-48a0-b136-b3b588f6d184.pdf

Regulatory Filings

Open in Viewer

Opens in native device viewer

26-March-2019 / 10:10 GMT/BST

Dissemination of a RegulatoryAnnouncement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement.

26March 2019

Tern Plc("Tern" or the "Company")

New commercial order forFundamentalVR

Tern Plc (AIM: TERN), the investment company specialising in the Internet of Things ("IoT"), is pleased to announce that FVRVS Limited ("FundamentalVR"),a leading Virtual Reality ("VR") training and data analysis technology pla+orm and one of its exis-ng por+olio companies, has secured an ini-al order of £150,000 to create a VR simula-on, for one of the world's leading pharmaceu-cal companies.

FundamentalVR's award winning pla+orm combines immersive virtual reality with cu4ng-edge hap-cs (the sense of touch) to create low-cost and scalable simulation experiences to offera new way to allow skills development for surgeonsand medical professionals.

The project is the first in a planned series of VR experiences thatFundamentalVR's client is commissioning to inform, educate and measure awareness and compliant, safe use of their pharma products. This first implementa-on will teach the method of ac-on and the pa-ent experience of a pharmaceu-cal product.

This mul--stage VR approach is expected to become a template for future product launches by the pharmaceu-cal client, which are intended to u-lise FundamentalVR'svirtual reality with hap-cs pla+orm.

Tern CEO, Al Sisto, said, "This is a new approach to pharma and medical device product introduc-ons, which we believe will accelerate the adop-on of new medical products in building out the use procedures in arepeatable prac-ce scenario were the individual's performance can be measured against a standard and his/her peers. FundamentalVR and its customers share the belief that the compara-ve data insights and measurements collected and available through the FundamentalVR pla+orm will have a profoundly posi-ve impact on medical outcomes and productsaround the world".

Thisannouncement contains inside informa-on for the purposes of Ar-cle 7 ofEU Regula-on 596/2014.

**ENDS**

Enquiries
Tern plc
Al Sisto, CEO
Sarah Payne,Finance Director
Via Newgate Communica-ons
Allenby Capital Limited
(Nomad and Joint broker)
David Worlidge/Alex Brearley
Tel: 0203 328 5656
Whitman Howard
(Joint broker)
Nick Lovering/ChristopherFurness
Tel: 020 7659 1234
Newgate Communica+ons Tel: 020 3757 6880

PR Elisabeth Cowell/Fiona Norman

ISIN: GB00BFPMV798 Category Code:UPD TIDM: TERN LEICode: 2138005F87SODHL9CQ36 Sequence No.: 7945 EQS News ID: 791671

End ofAnnouncementEQS News Service

Talk to a Data Expert

Have a question? We'll get back to you promptly.